Evidence map›Paper›PMID 37373448›Full record

ReviewInternational journal of molecular sciences2023

Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation.

Kamila Szumilas, Aleksandra Wilk, Piotr Wiśniewski, Anna Gimpel, Violetta Dziedziejko, Markus Kipp, Andrzej Pawlik

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
18.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Kamila SzumilasDepartment of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland.ORCID 0000-0002-5635-1630
Aleksandra WilkDepartment of Histology and Embryology, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0002-1542-8371
Piotr WiśniewskiDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.
Anna GimpelDepartment of Histology and Embryology, Pomeranian Medical University, 70-111 Szczecin, Poland.
Violetta DziedziejkoDepartment of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0003-4809-415X
Markus KippInstitute of Anatomy, Rostock University Medical Center, Gertrudenstrasse 9, 18057 Rostock, Germany.ORCID 0000-0001-5043-9052
Andrzej PawlikDepartment of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland.ORCID 0000-0001-6557-1208
Pomeranian Medical University · PLUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal transplantation is now the best treatment for end-stage renal failure. To avoid rejection and prolong graft function, organ recipients need immunosuppressive therapy. The immunosuppressive drugs used depends on many factors, including time since transplantation (induction or maintenance), aetiology of the disease, and/or condition of the graft. Immunosuppressive treatment needs to be personalised, and hospitals and clinics have differing protocols and preparations depending on experience. Renal transplant recipient maintenance treatment is mostly based on triple-drug therapy containing calcineurin inhibitors, corticosteroids, and antiproliferative drugs. In addition to the desired effect, the use of immunosuppressive drugs carries risks of certain side effects. Therefore, new immunosuppressive drugs and immunosuppressive protocols are being sought that exert fewer side effects, which could maximise efficacy and reduce toxicity and, in this way, reduce both morbidity and mortality, as well as increase opportunities to modify individual immunosuppression for renal recipients of all ages. The aim of the current review is to describe the classes of immunosuppressive drugs and their mode of action, which are divided by induction and maintenance treatment. An additional aspect of the current review is a description of immune system activity modulation by the drugs used in renal transplant recipients. Complications associated with the use of immunosuppressive drugs and other immunosuppressive treatment options used in kidney transplant recipients have also been described.

Indexed as

Kidney TransplantationCalcineurin InhibitorsGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsCalcineurin InhibitorsImmunosuppressive Agentsimmunosuppressive drugsimmunosuppressive treatmentrenal transplantation

Identifiers

PMID37373448
PMCPMC10298917
OpenAlexW4381252533

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.